Cannabics Pharmaceuticals, Inc. (CNBX)


Cannabics Pharmaceuticals, Inc is a biotech company that produces proprietary technologies for medical cannabis therapies.

The company’s flagship product is the Cannabics SR, a sustained release cannabis capsule to provide palliative care to cancer patients. Using a patented formulation, Cannabics SR capsules contain a pure concentrate of cannabinoids from cannabis strains which the company itself selects and breeds. Each capsule is designed to provide 10-12 hours of therapeutic effects, thus allowing for a once-a-day dosage.

Other products in the company’s line are Cannabics IN, a capsule for dry powder inhalers, and Cannabics VP, a condensed pill for standard vaporizers. As of 2013, the company’s products are circulating through five Israel hospitals. It is noted that Israel permits medical marijuana use for patients with cancer and pain-related illnesses.

Cannabics Pharmaceuticals is based in Bethesda, Maryland. According to the company website, it is developing advanced cannabinoid-based therapies through its research and development arm in Israel. It is also collaborating with medical centers in Israel, the US (including states like Colorado and California), and Europe (including countries like Spain, Czech Republic, and the Netherlands) to launch clinical studies on their products.

Cannabics Pharmaceuticals, Inc is a fairly new name in the marijuana industry. It is a subsidiary of Cannabics, Inc, which was founded in 2012 by researchers in molecular biology, pharmacology, and cancer research. The pharmaceuticals company was also formerly known as Thrust Energy Corp until 2011, and as American Mining Corporation just until June 2014.

The company is currently traded in OTC markets as CNBX, with a market cap of USD 32.7 M. Its key executives are Dr. Zohar Koren, Co-founder and CEO; Dr. Eyal Ballan, Co-founder and CTO; and Itamar Borochov, VP of Marketing.

Yahoo! Finance: CNBX News

Latest Financial News for CNBX

Cannabics Pharmaceuticals to Present Research Data at the 2nd International Cannabinoid Derived Pharmaceuticals Summit in Boston, MA

TEL AVIV, Israel and BETHESDA, Maryland, Sept. 12, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabis based cancer medicine, today announced that its Scientific Director, Dr. Ilan Hochman, is scheduled to present research data from cannabinoid tests on live cancer biopsies at the 2nd  International Cannabinoid Derived Pharmaceuticals Summit, to be held in Boston, MA, on September 10-12, 2019. The company has been focusing on developing solutions for bringing cannabis based solutions into the mainstream of cancer treatments together with existing therapeutic approaches.

'Algorithms Manage Everything': One Israeli Company's Mission To Make Marijuana Growing Effortless

Cannabis cultivation is a meticulous process that involves more than just planting a seed or a clone and watering it regularly. Luckily, there are solutions that make growing weed easier, even in the comfort of one’s home. One of these solutions is Seedo, a special pod that takes care of the entire growing process and can be controlled through an app on a smartphone.

Wize Pharma Completes Milestone for Joint Venture With Cannabics Pharmaceuticals; Companies to Develop Cannabinoid Ophthalmic Treatments

HOD HASHARON, Israel, June 28, 2019 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced today that the Company and Cannabics Pharmaceuticals (CNBX) have together created and adopted a business plan for their joint venture (JV), a new entity focused on the research and development of cannabinoid formulations to treat ophthalmic conditions. Creation and approval of a business plan for the JV was a condition for the planned venture to move forward. Having assessed the regulatory pathway for eyedrops containing cannabinoids or cannabinoid strings, we are eagerly engaging in technology development and clinical advancement.

/C O R R E C T I O N -- Cannabics Pharmaceuticals Inc./

In the news release, Cannabics Pharmaceuticals Appoints Two Independent Directors, issued June 25, 2019 by Cannabics Pharmaceuticals Inc. over PR Newswire, we are advised by the company that the 5th paragraph, 1st sentence, should read "Mr. Ballan served as Senior Executive Vice President and General Counsel at Gazit Globe, a Tel Aviv Stock Exchange listed company that is part of the TA-35 and Real-Estate 15 indexes in Israel." rather than as originally issued inadvertently. TEL AVIV, Israel and BETHESDA, Maryland, June 25, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has appointed two new independent directors to its board of directors, Dr. Estery Giloz-Ran and Eran Ballan, Esq.

Cannabics Pharmaceuticals to Participate at the LIFT & Co. Conference in Toronto, Canada

TEL AVIV, Israel and BETHESDA, Maryland, June 4, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it will be participating at the LIFT & Co. Conference at the Metro Toronto Convention Centre in Toronto, Canada. "This year's conference in Toronto is exciting because it is the largest premier industry business conference event in Canada," stated Mr. Barad.